Shanker Gupta, PhD, named PDA JPST Acting Editor-in-Chief
Please note: Some pages on PDA's main site (www.pda.org) and the PDA Letter (https://www.pda.org/pda-letter-portal/home) may not currently be available due to technical issues. The JPST site is unaffected. Thank you for your patience while PDA works to resolve the issue.
Shanker L. Gupta, PhD, is now serving as the Acting Editor-in-Chief of the PDA Journal of Pharmaceutical Science and Technology (JPST), while PDA conducts the search for a permanent Editor. Richard V. Levy, PhD, has retired as Editor-in-Chief after almost four years. Dr. Gupta joined the reconstitued Journal Editorial Board in 2019 and volunteered as an Associate Editor in 2020. In that capacity, he assisted Dr. Levy evaluate and manage JPST submissions. He has been a PDA member for more than 30 years.
Dr. Gupta has worked with the U.S. National Institutes of Health for almost 20 years, currently as a senior scientist in the Division of Cancer Prevention of the National Cancer Institute and consulting with the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases. At NIH, he has been responsible for managing multiple translational projects designed to generate clinical product for use in Phase I and Phase 2 clinical trials. Gupta also collaborates with contract teams and actively participates in the design and development of formulations of several promising agents that have resulted in patent filings. He has supported over 40 IND submissions.
Dr. Gupta holds a BS (Hons) in pharmacy from the University of Florida and a PhD in pharmaceutical chemistry from the University of Michigan, Ann Arbor. Prior to joining NIH, he was a project leader in sterile products development at Abbott Laboratories and filed the IND for the expanded use of a lung surfactant product (Survanta®), which was the first product of its kind for neonatal respiratory distress syndrome. Dr. Gupta has published more than 20 papers in various peer-reviewed journals and contributed to books.
Accepted Articles
Featured Articles
PDA President Richard Johnson's 2022 Message
2021 was a challenging year for everyone, and PDA was not an exception. Last year at this time I shared the impact that the pandemic had on PDA in 2020. We were looking forward to a brighter 2021, and in some ways it was better. Vaccines for COVID were developed, proven, and released in record speed, and our community had a significant role in making that possible.
We also brought together industry, suppliers and regulators in a joint effort to address these challenges. Nonetheless, the pandemic continued throughout 2021 and into the present year. We have had positive signs, followed by resurgence of infections and the resulting societal and human impact. For PDA, it had the effect of making us postpone our return to in-person gatherings, and shift (again) to all-virtual. Of more importance has been the staggering human cost, that as of January 27, 2022, has resulted in over 5.5 million deaths, and more than 364 million cases worldwide. In addition to the terrible health impacts, the control measures that are continuing to be implemented have affected many more people’s livelihood and social activity.
